Oncolytics Tax Provision from 2010 to 2025

ONCY Stock  USD 0.77  0.00  0.000003%   
Oncolytics Biotech Tax Provision yearly trend continues to be fairly stable with very little volatility. Tax Provision will likely drop to about 84.1 K in 2025. Tax Provision is the amount set aside by Oncolytics Biotech to cover any estimated taxes for the current period. It reflects Oncolytics Biotech's expected tax liabilities. View All Fundamentals
 
Tax Provision  
First Reported
2010-12-31
Previous Quarter
99.9 K
Current Value
84.1 K
Quarterly Volatility
136 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 88.5 K, Interest Expense of 637.6 K or Selling General Administrative of 19.4 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 5.18. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
Check out the analysis of Oncolytics Biotech Correlation against competitors.
For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Latest Oncolytics Biotech's Tax Provision Growth Pattern

Below is the plot of the Tax Provision of Oncolytics Biotech over the last few years. It is the amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities. Oncolytics Biotech's Tax Provision historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
Tax Provision10 Years Trend
Pretty Stable
   Tax Provision   
       Timeline  

Oncolytics Tax Provision Regression Statistics

Arithmetic Mean71,642
Geometric Mean0.00
Coefficient Of Variation189.78
Mean Deviation79,840
Median9,374
Standard Deviation135,960
Sample Variance18.5B
Range548K
R-Value0.26
Mean Square Error18.5B
R-Squared0.07
Significance0.33
Slope7,460
Total Sum of Squares277.3B

Oncolytics Tax Provision History

202584.1 K
202499.9 K
2023111 K
202284 K
202149.4 K
2019null
2018548 K

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Tax Provision, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tax Provision99.9 K84.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.